Home
Market
IPO
Screener
Bundles
Super Investors
Sector
Discover
TickerPlus
Account
Symbiotec Pharmalab
Consolidated
Standalone
Peers
P&L
Balance Sheet
Cash Flows
Corp. Action
News
Ticker
>
Company
>
Symbiotec Pharmalab share price
Symbiotec Pharmalab Ltd.
414
0
0
The company is currently not listed and is under IPO, so all the data might not be available.
Peer Comparison
View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.
Ratios
Sales Growth
1 Year
19.52%
3 Year
2.65%
5 Year
5%
Profit Growth
1 Year
492.54%
3 Year
-13.11%
5 Year
14.05%
ROE%
1 Year
12.41%
3 Year
6.13%
5 Year
11.61%
ROCE %
1 Year
15.75%
3 Year
9.24%
5 Year
14.76%
Debt/Equity
0.0679
Price to Cash Flow
0
Interest Cover Ratio
0
CFO/PAT
(5 Yr. Avg.)
0
Strengths
The company has significantly decreased its debt by
55.55
Cr.
Company is virtually debt free.
The company has an efficient Cash Conversion Cycle of
0
days.
Limitations
The company has shown a poor profit growth of
-13.1052664029927
% for the Past 3 years.
The company has shown a poor revenue growth of
2.64518595561334
% for the Past 3 years.
Company has a poor ROE of
6.12866666666667
% over the past 3 years.
The company has a low EBITDA margin of
0
% over the past 5 years.
Profit & Loss
(All Figures in Cr. Adjusted EPS in Rs.)
PARTICULARS
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Net Sales
531.19
622.86
633.85
563.59
673.61
Total Expenditure
411.8
420.5
528.55
483.49
530.67
Operating Profit
119.39
202.37
105.3
80.09
142.94
Other Income
3.17
9.01
5.65
12.37
19.76
Interest
10.61
6.52
3.07
8.05
7.54
Depreciation
21.16
22.18
25.11
27.62
37.26
Exceptional Items
0
0
0
-64.57
0
Profit Before Tax
90.79
182.67
82.77
-7.78
117.9
Tax
18.27
47.11
21.04
14.88
28.95
Net Profit
72.52
135.56
61.73
-22.66
88.95
Adjusted EPS (Rs.)
13.26
24.79
11.29
-4.14
16.27
Balance Sheet
(All Figures are in Crores.)
Particulars
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Equity and Liabilities
Share Capital
10.94
10.94
10.94
10.94
10.94
Total Reserves
486.9
622.42
684.25
661.88
750.2
Borrowings
2.47
1.46
0.73
1.41
1.12
Other N/C liabilities
20.7
25.5
26.42
26.71
26.28
Current liabilities
248.56
181.55
172.15
214.19
298.66
Total Liabilities
769.55
841.87
894.48
915.12
1087.19
Assets
Net Block
229.62
247.58
266.09
265.65
323.82
Capital WIP
28.15
26.73
22.62
73.9
19.36
Intangible WIP
2.35
0
0
0
0
Investments
107.1
122.15
130.17
65.6
42.25
Loans & Advances
8.92
30.57
57.48
123.33
200.93
Other N/C Assets
2.32
2.37
2.51
0.01
2.54
Current Assets
391.1
412.46
415.62
386.62
498.29
Total Assets
769.55
841.87
894.48
915.12
1087.19
* Other Non-current Liabilities include Net deferred Liabilities
Cash Flows
(All Figures are in Crores.)
PARTICULARS
Mar 2023
Mar 2024
Profit from operations
-7.78
117.9
Adjustment
91.15
25.36
Changes in Assets & Liabilities
25.8
39.29
Tax Paid
-15.82
-35.09
Operating Cash Flow
93.35
147.46
Investing Cash Flow
-132.5
-80.8
Financing Cash Flow
36.53
-62.98
Net Cash Flow
-2.62
3.67
Corporate Actions
Dividend
Bonus
Rights
Split
Company News
Symbiotec Pharmalab files preliminary papers to raise Rs 2,180 crore via IPO
20 Dec, 1:13 PM
Last Updated on:
Brief about Symbiotec Pharmalab
x
Ratio Delete Confirmation
×
Are you sure you want to DELETE
from your ratio list? This will also hide it from all other companies that you analyze.
X